Clinical trial results announced at the Transcatheter Therapeutics conference in San Francisco headlined the medtech research and development news last week. Noteworthy "commercial" developments in late October include iCad’s decision to sell its Xoft brachytherapy business to Elekta and Butterfly Network's plans to work with Forest Neurotech on brain-computer interfaces.
Long-term results from two major clinical trials support transcatheter aortic valve replacement (TAVR) as an alternative to surgery, even in patients at low risk for surgical complications.
Edwards Lifesciences’ Sapien line of balloon-expandable TAVR and Medtronic’s CoreValve line of self-expanding TAVR systems are already approved...